466 related articles for article (PubMed ID: 27735912)
41. Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Rosa GM; Bianco D; Valbusa A; Massobrio L; Chiarella F; Brunelli C
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1491-1502. PubMed ID: 27715344
[TBL] [Abstract][Full Text] [Related]
42. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Fox KA; Granger CB; Jolly S; Rupprecht HJ; Widimsky P; Yusuf S;
Am Heart J; 2008 Dec; 156(6):1080-1088.e1. PubMed ID: 19033002
[TBL] [Abstract][Full Text] [Related]
43. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
James SK; Roe MT; Cannon CP; Cornel JH; Horrow J; Husted S; Katus H; Morais J; Steg PG; Storey RF; Stevens S; Wallentin L; Harrington RA;
BMJ; 2011 Jun; 342():d3527. PubMed ID: 21685437
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of prasugrel in a US managed care population.
Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES
J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985
[TBL] [Abstract][Full Text] [Related]
45. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
47. Ticagrelor for acute coronary syndrome?
Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607
[TBL] [Abstract][Full Text] [Related]
48. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
[TBL] [Abstract][Full Text] [Related]
49. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
50. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.
Crespin DJ; Federspiel JJ; Biddle AK; Jonas DE; Rossi JS
Value Health; 2011 Jun; 14(4):483-91. PubMed ID: 21669373
[TBL] [Abstract][Full Text] [Related]
51. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
[TBL] [Abstract][Full Text] [Related]
52. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
[TBL] [Abstract][Full Text] [Related]
53. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
[TBL] [Abstract][Full Text] [Related]
54. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
55. Ticagrelor: a review of its use in adults with acute coronary syndromes.
Dhillon S
Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
[TBL] [Abstract][Full Text] [Related]
56. Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Johnston SS; Bell K; Gdovin J; Jing Y; Graham J
Hosp Pract (1995); 2012 Feb; 40(1):15-23. PubMed ID: 22406879
[TBL] [Abstract][Full Text] [Related]
57. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
58. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Fitchett D; Eikelboom J; Fremes S; Mazer D; Singh S; Bittira B; Brister S; Graham J; Gupta M; Karkouti K; Lee A; Love M; McArthur R; Peterson M; Verma S; Yau T
Can J Cardiol; 2009 Dec; 25(12):683-9. PubMed ID: 19960127
[TBL] [Abstract][Full Text] [Related]
59. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
60. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
